MAX1
Based on 1 Customer Validation
MAX1 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX1 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX1 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX1 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.31%
- CAS. Nr.: 487036-63-5
- Formel: C107H201N29O21
- Molecular Weight:2229.92
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biologische Aktivität
Beschreibung
In Vitro
MAX1 (0.5 wt%) prepared at 37°C in DMEM forms a network of ~3 nm diameter fibrils, as visualized via negatively stained TEM[1].
MAX1 hydrogel (0.5 wt%) encapsulation of 1 μg NGF does not change the physical gelation, shear-thinning, or rehealing properties of the hydrogel[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:C3H10t1/2 mesenchymal stem cells
-
Concentration:0.5 wt%
-
Incubation Time:3 h (post-delivery viability assessment)
-
Result:Showed that the majority of C3H10t1/2 cells remained viable (stained green) after shear-thin delivery.
Had a level of cell death nearly identical to control cells encapsulated in MAX8 hydrogel without shear-thin delivery.
-
Cell Line:PC12 pheochromocytoma cells
-
Concentration:0.5 wt% MAX8; 1 μg NGF
-
Incubation Time:7 days
-
Result:PC12 cells exposed to NGF released from 0.5 wt% MAX8 developed an extensive network of neurite-like extensions after 7 days, comparable to cells treated with 100 ng/mL NGF added directly to media (with periodic NGF replenishment).
-
Cell Line:PC12 pheochromocytoma cells
-
Concentration:0.5 wt% MAX8; 1 μg NGF
-
Incubation Time:3 days, 7 days
-
Result:PC12 cells in direct contact with NGF-loaded 0.5 wt% MAX8 formed neurite-like extensions in 67% of cells after 3 days and 76% of cells after 7 days, with no statistical difference compared to cells treated directly with NGF in media.
Contact with MAX8 alone did not induce neurite formation.
-
Cell Line:PC12 pheochromocytoma cells
-
Concentration:0.5 wt% MAX8; 1 μg NGF; 1 μg NGF/BDNF (bolus-delivered)
-
Incubation Time:14, 21, 28 days (MAX8 incubation before PC12 exposure); up to 28 days (bolus vs encapsulated incubation)
-
Result:NGF released from MAX8 incubated for 21 days induced neurite-like extensions in 88% of PC12 cells; NGF from MAX8 incubated for 28 days induced extensions in 86% of cells.
Levels of encapsulated NGF/BDNF in media remained constant for at least 21 days, whereas bolus-delivered NGF/BDNF was almost undetectable after 18 days.
Unencapsulated NGF had a half-life of ~3.5 days, and unencapsulated BDNF had a half-life of ~3.4 days.
-
Cell Line:3T3 mouse embryonic fibroblasts, PC12 pheochromocytoma cells
-
Concentration:0.5 wt% MAX8; 1 μg NGF; 1 μg NGF or BDNF
-
Incubation Time:24 hours (3T3 cells); 24 hours (MAX8 media harvest), 1 hour (PC12 cell incubation)
-
Result:3T3 cells proliferated 17-35% more in response to NGF released from MAX8, comparable to cells treated with unencapsulated NGF.
Media from NGF-loaded MAX8 induced increased phosphorylated ERK levels in PC12 cells, confirming activation of the NGF signaling pathway.
-
Cell Line:MC3 T3-E1 preosteoblast cells
-
Concentration:0.5, 0.75, 1, 1.5, 2 wt%
-
Incubation Time:24 hours
-
Result:Supported ~99% cell viability across all hydrogel concentrations (corresponding to stiffnesses of ~270-3600 Pa) after 24 hours.
Allowed cells to display a well-spread, fibroblast-like morphology.
Enabled cells on 0.75 wt% hydrogels to show stretched F-actin fibers and cellular extensions, indicating cytoskeletal development and strong adhesion to the hydrogel surface.
-
Cell Line:DAOY human medulloblastoma cells
-
Concentration:0.5 wt% MAX8; 0 nM, 1.6 nM, 8 nM, 40 nM vincristine
-
Incubation Time:2 days
-
Result:Caused minimal cell death with pure MAX8 hydrogel (0 nM vincristine).
Increased cell death with increasing encapsulated vincristine concentration, reaching an IC50 when 8 nM vincristine was encapsulated.
Confirmed higher encapsulated vincristine concentrations correlated with increased rounded, opaque dead cells via optical micrographs.
-
Cell Line:DAOY human medulloblastoma cells
-
Concentration:0.5 wt% MAX8; 0 µM, 10 µM, 500 µM vincristine
-
Incubation Time:1 hour, 3-7 days, 10-14 days, 17-21 days, 24-28 days
-
Result:Induced significantly greater cell death in groups exposed to vincristine-loaded MAX8 hydrogels compared to pure MAX8 hydrogel across all time intervals, including the 24-28 day interval.
Showed higher initial encapsulated vincristine concentrations correlated with increased cell death.
Chemical Information
-
CAS. Nr. 487036-63-5
-
Appearance Solid
-
Molecular Weight 2229.92
-
Formel C107H201N29O21
-
Color White to off-white
-
Sequence
Val-Lys-Val-Lys-Val-Lys-Val-Lys-Val-{d-Pro}-Pro-Thr-Lys-Val-Lys-Val-Lys-Val-Lys-Val-NH2
-
Sequence Shortening
VKVKVKVKV-{d-Pro}-PTKVKVKVKV-NH2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (11.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
3D Hydrogel Synthetic Scaffold Culture
3D hydrogel synthetic scaffold culture embeds cells, spheroids, organoids, or tissue fragments inside a hydrated crosslinked polymer network so that cells receive matrix and cell-cell cues in three dimensions rather than from a flat plastic surface. A literature-supported model protocol is PEG-4MAL hydrogel culture, in which four-arm maleimide-terminated PEG is functionalized with cysteine-containing adhesive peptides such as RGD and crosslinked with protease-degradable peptides such as GPQ-W; this creates a defined, modular scaffold that supports human organoid generation and culture. The readouts are scaffold-supported growth, morphology, lumen formation, budding, viability, proliferation, lineage-marker expression, and matrix-dependent expansion or differentiation; reported assays include transmitted-light imaging, immunofluorescence, in situ hybridization, qRT-PCR, and rheological characterization.
-
Trophoblast Invasion Assay
The trophoblast invasion assay is commonly based on the Matrigel-coated Transwell invasion system, in which invasive cells migrate through a reconstituted basement membrane matrix toward a chemoattractant gradient, thereby modeling extracellular matrix (ECM) penetration and invasive behavior in vitro. The readout is typically the number of cells that traverse the Matrigel barrier and attach to the lower surface of a porous membrane, reflecting invasive capacity through ECM-like substrates and basement membrane components. This system was originally developed to quantify invasive cell behavior using Matrigel as a basement membrane analog in a Boyden chamber format.
-
PC12 NGF-Induced Neuronal Differentiation Culture
PC12 cells are a rat adrenal pheochromocytoma clonal line that responds to NGF by stopping proliferation and extending branching neurite-like processes; after longer NGF exposure, cells develop long processes and neuronal-like ultrastructural and functional features. NGF-induced differentiation is read out mainly by neurite outgrowth, reduced proliferation, microtubule assembly, and neuronal differentiation-associated proteins such as MAPs, tau, GAP-43, and synapsin-1.
-
Research Protocol for Drug Screening technologies
Drug screening technologies are experimental and computational strategies used to identify small molecules or chemical probes that modulate a defined molecular target, signaling pathway, cellular phenotype, disease model, or patient-derived response profile. High-throughput screening tests many compounds in miniaturized assay formats, while quantitative high-throughput screening tests compounds across concentration ranges so that potency and efficacy can be inferred from concentration-response behavior rather than from a single-point signal. The core biological function of a drug-screening strategy is to connect compound exposure with measurable pathway activity, target modulation, cell-state change, viability, cytotoxicity, morphology, or disease-relevant phenotype. Assay performance must be evaluated before screening because hit identification depends on the separation between positive and negative controls, control variability, plate effects, outliers, and the statistical framework
-
PC12 NGF-induced neuronal-like differentiation
PC12 cells are a rat adrenal pheochromocytoma-derived clonal cell line that responds to nerve growth factor by stopping proliferation and extending neurites, producing a sympathetic neuron-like phenotype used to study neuronal differentiation and neurite outgrowth. NGF acts through TrkA-dependent signaling, and neurite outgrowth is associated with ERK/Akt signaling, microtubule organization, neuronal-marker expression, and increased electrophysiological neuronal features such as sodium-channel density. The main assay readout is morphological differentiation, usually measured as the percentage of neurite-bearing cells, neurite length, neurite number, or total neurite length per cell. Additional readouts include GAP-43, tyrosine hydroxylase, βIII-tubulin, neurofilament, synapsin I, synaptophysin, ERK phosphorylation, Akt phosphorylation, and sodium-channel current density.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (290 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Haines-Butterick L, et al. Controlling hydrogelation kinetics by peptide design for three-dimensional encapsulation and injectable delivery of cells. Proceedings of the National Academy of Sciences of the United States of America. 2007 May 08;104(19):7791-6. [Content Brief]
[2]. Lindsey S, et al. Beta Hairpin Peptide Hydrogels as an Injectable Solid Vehicle for Neurotrophic Growth Factor Delivery. Biomacromolecules. 2015 Sep 14;16(9):2672-83. [Content Brief]
[3]. Hule RA, et al. Correlations between structure, material properties and bioproperties in self-assembled beta-hairpin peptide hydrogels. Faraday discussions. 2008;139:251-64; discussion 309-25, 419-20. [Content Brief]
[4]. Branco MC, et al. Fast dynamics of semiflexible chain networks of self-assembled peptides. Biomacromolecules. 2009 Jun 08;10(6):1374-80. [Content Brief]
[5]. Leonard SR, et al. Solid-state NMR evidence for β-hairpin structure within MAX8 designer peptide nanofibers. Biophysical journal. 2013 Jul 02;105(1):222-30. [Content Brief]
[6]. Sun JE, et al. Sustained release of active chemotherapeutics from injectable-solid β-hairpin peptide hydrogel. Biomaterials science. 2016 May 26;4(5):839-48. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4484 mL | 2.2422 mL | 4.4845 mL | 11.2112 mL |
| 5 mM | 0.0897 mL | 0.4484 mL | 0.8969 mL | 2.2422 mL | |
| 10 mM | 0.0448 mL | 0.2242 mL | 0.4484 mL | 1.1211 mL |